OCS Liver PROTECT Continued Access Protocol

Liver Transplant Clinical Trial

Official title: Continued Access Protocol To Evaluate the Effectiveness of the Portable Organ Care System (OCS) Liver for Preserving and Assessing Donor Livers for Transplantation.

Status Completed

Clinical Trial Summary

Continued Access Protocol to evaluate the effectiveness of the OCS Liver System to preserve and assess donor livers.

Clinical Trial Description

A prospective, single arm, continued access protocol to evaluate the effectiveness of the OCS Liver System to preserve and assess donor livers having one or more of the following characteristics:

1. Donor age equal to or greater than 40 years old, or

2. Expected cross clamp time of 6 hours or greater, or

3. Donor after circulatory death (DCD) with age less than or equal to 55 years; or

4. Steatotic lever >0% and less than or equal to 40% at time of retrieval, based on pre-retrieval histology)

A maximum of 21 sites will enroll up to 184 transplanted liver recipients. The primary effectiveness endpoint will be the incidence of Early Allograft Dysfunction (EAD) or primary non-function.

All recipients will be followed for 24 months from the date of transplantation (some of which will be post-market). ;

Related Conditions & MeSH terms

• Liver Transplant

• NCT number: NCT04186221
• Study type: Interventional
• Source: TransMedics
• Status: Completed
• Phase: N/A
• Start date: February 3, 2020
• Completion date: February 2, 2023